1. Home
  2. MESO vs EVLV Comparison

MESO vs EVLV Comparison

Compare MESO & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • EVLV
  • Stock Information
  • Founded
  • MESO 2004
  • EVLV 2013
  • Country
  • MESO Australia
  • EVLV United States
  • Employees
  • MESO N/A
  • EVLV N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • EVLV Computer peripheral equipment
  • Sector
  • MESO Health Care
  • EVLV Technology
  • Exchange
  • MESO Nasdaq
  • EVLV Nasdaq
  • Market Cap
  • MESO 1.3B
  • EVLV 1.4B
  • IPO Year
  • MESO N/A
  • EVLV N/A
  • Fundamental
  • Price
  • MESO $18.41
  • EVLV $7.46
  • Analyst Decision
  • MESO Buy
  • EVLV Strong Buy
  • Analyst Count
  • MESO 2
  • EVLV 4
  • Target Price
  • MESO $24.00
  • EVLV $8.88
  • AVG Volume (30 Days)
  • MESO 283.4K
  • EVLV 4.3M
  • Earning Date
  • MESO 08-28-2025
  • EVLV 08-14-2025
  • Dividend Yield
  • MESO N/A
  • EVLV N/A
  • EPS Growth
  • MESO N/A
  • EVLV N/A
  • EPS
  • MESO N/A
  • EVLV N/A
  • Revenue
  • MESO $17,198,000.00
  • EVLV $121,011,000.00
  • Revenue This Year
  • MESO $288.50
  • EVLV $31.07
  • Revenue Next Year
  • MESO $173.73
  • EVLV $17.67
  • P/E Ratio
  • MESO N/A
  • EVLV N/A
  • Revenue Growth
  • MESO 191.39
  • EVLV 36.64
  • 52 Week Low
  • MESO $7.09
  • EVLV $2.04
  • 52 Week High
  • MESO $22.00
  • EVLV $8.91
  • Technical
  • Relative Strength Index (RSI)
  • MESO 70.00
  • EVLV 41.95
  • Support Level
  • MESO $15.60
  • EVLV $7.63
  • Resistance Level
  • MESO $16.19
  • EVLV $8.02
  • Average True Range (ATR)
  • MESO 0.54
  • EVLV 0.40
  • MACD
  • MESO 0.17
  • EVLV -0.13
  • Stochastic Oscillator
  • MESO 86.95
  • EVLV 10.71

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: